Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Katie L Owen"'
Autor:
Damien J Zanker, Alex J Spurling, Natasha K Brockwell, Katie L Owen, Jasmine M Zakhour, Tina Robinson, Hendrika M Duivenvoorden, Paul J Hertzog, Stefanie R Mullins, Robert W Wilkinson, Belinda S Parker
Publikováno v:
Clinical & Translational Immunology, Vol 9, Iss 9, Pp n/a-n/a (2020)
Abstract Objectives Loss of tumor‐inherent type I interferon (IFN) signalling has been closely linked to accelerated metastatic progression via decreased immunogenicity and antitumor immunity. Previous studies in murine models of triple‐negative
Externí odkaz:
https://doaj.org/article/61578605bee846698ae1d74398aee779
Autor:
Louise Kostos, James P. Buteau, Theresa Yeung, Juliana Di Iulio, Jing Xie, Anthony Cardin, Kwang Y. Chin, Brittany Emmerson, Katie L. Owen, Belinda S. Parker, Heidi Fettke, Luc Furic, Arun A. Azad, Michael S. Hofman
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Background[177Lu]Lu-PSMA is a radioligand therapy used in metastatic castration-resistant prostate cancer (mCRPC). Despite a survival benefit, the responses for many patients receiving [177Lu]Lu-PSMA are not durable, and all patients eventually devel
Externí odkaz:
https://doaj.org/article/ee75493d95874a12b67e6d0f0cb88f42
Autor:
Belinda S. Parker, Elgene Lim, Phillip K. Darcy, Sherene Loi, Franco Caramia, Nikola Baschuk, Hendrika M. Duivenvoorden, Jai Rautela, Alex Spurling, Damien Zanker, Katie L. Owen, Natasha K. Brockwell
Figure legends for supplementary figures 1, 2 & 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3499bd9355a04dac47fccd01d1025b6
https://doi.org/10.1158/2326-6066.22537178.v1
https://doi.org/10.1158/2326-6066.22537178.v1
Autor:
Belinda S. Parker, Elgene Lim, Phillip K. Darcy, Sherene Loi, Franco Caramia, Nikola Baschuk, Hendrika M. Duivenvoorden, Jai Rautela, Alex Spurling, Damien Zanker, Katie L. Owen, Natasha K. Brockwell
The effect of combination treatment on T cell activation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d4f94fe5a5e07717a1c3e0e4da0cb1a
https://doi.org/10.1158/2326-6066.22537181.v1
https://doi.org/10.1158/2326-6066.22537181.v1
Autor:
Belinda S. Parker, Elgene Lim, Phillip K. Darcy, Sherene Loi, Franco Caramia, Nikola Baschuk, Hendrika M. Duivenvoorden, Jai Rautela, Alex Spurling, Damien Zanker, Katie L. Owen, Natasha K. Brockwell
The lack of targeted therapies available for triple-negative breast cancer (TNBC) patients who fail to respond to first-line chemotherapy has sparked interest in immunotherapeutic approaches. However, trials utilizing checkpoint inhibitors targeting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12dc36d7bdeb3d3c3e14c923091f5dc9
https://doi.org/10.1158/2326-6066.c.6548339.v1
https://doi.org/10.1158/2326-6066.c.6548339.v1
Publikováno v:
Cancer Immunology, Immunotherapy. 70:2125-2138
Competent type I IFN signaling is the lynchpin of most immune surveillance mechanisms and has recently proven critical to the efficacy of several anticancer agents. Expression of the type I IFN receptor, IFNAR, underpins type I IFN responsiveness in
Autor:
Mohammadreza Alizadeh-Ghodsi, Katie L. Owen, Scott L. Townley, Damien Zanker, Samuel P.G. Rollin, Adrienne R. Hanson, Raj Shrestha, John Toubia, Tessa Gargett, Igor Chernukhin, Jennii Luu, Karla J. Cowley, Ashlee Clark, Jason S. Carroll, Kaylene J. Simpson, Jean M. Winter, Mitchell G. Lawrence, Lisa M. Butler, Gail P. Risbridger, Benjamin Thierry, Renea A. Taylor, Theresa E. Hickey, Belinda S. Parker, Wayne D. Tilley, Luke A. Selth
Inhibiting the androgen receptor (AR), a ligand-activated transcription factor, with androgen deprivation therapy is a standard-of-care treatment for metastatic prostate cancer. Paradoxically, activation of AR can also inhibit the growth of prostate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9d9962b6320e3d931944ba5a332aee2
https://hdl.handle.net/11541.2/30271
https://hdl.handle.net/11541.2/30271
Autor:
Corinne Ooi, Alex Spurling, Jane Fox, Vinod Ganju, Linden J. Gearing, Michelle White, Beena Kumar, Damien Zanker, Timothy J. Molloy, Hendrika M. Duivenvoorden, Helen E. Cumming, Jasmine M. Zakhour, Kate Harvey, Siddhartha Deb, Tina Robinson, Marion Harris, Paul J. Hertzog, Natasha K Brockwell, Jai Rautela, Sandra O’ Toole, Jacqui Thomson, Chia-Ling Chan, Niantao Deng, Belinda S. Parker, Katie L. Owen, Alexander Swarbrick, Nicole Potasz
Publikováno v:
npj Precision Oncology, Vol 3, Iss 1, Pp 1-13 (2019)
NPJ Precision Oncology
NPJ Precision Oncology
Patients diagnosed with triple negative breast cancer (TNBC) have an increased risk of rapid metastasis compared to other subtypes. Predicting long-term survival post-chemotherapy in patients with TNBC is difficult, yet enhanced infiltration of tumor
Autor:
Belinda S. Parker, Katie L. Owen
Publikováno v:
Molecular Immunology. 110:57-68
Bone metastasis is a fatal consequence of a subset of solid malignancies that fail to respond to conventional therapies. While a myriad of factors contribute to osteotropism and disseminated cell survival and outgrowth in bone, efforts to inhibit tum
Autor:
Alex Spurling, John M. Mariadason, Lisa M. Butler, Linden J. Gearing, Niall M. Corcoran, Stefano Mangiola, Katie L. Owen, Peter I. Croucher, Natasha K Brockwell, Daniel L. Roden, Alexander Swarbrick, Ruth J. Lyons, Weng Hua Khoo, Matthew K.H. Hong, Anupama Pasam, Chia Ling Chan, Andrew Ryan, Michelle M. McDonald, Vanessa M. Hayes, Hendrika M. Duivenvoorden, Tri Giang Phan, Damien Zanker, Paul J. Hertzog, Shahneen Sandhu, Christopher M. Hovens, Marek Cmero, Belinda S. Parker
Publikováno v:
EMBO Reports
The latency associated with bone metastasis emergence in castrate‐resistant prostate cancer is attributed to dormancy, a state in which cancer cells persist prior to overt lesion formation. Using single‐cell transcriptomics and ex vivo profiling,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d1e84dc3ba88b9fe110748c95dfd5f9